Over the last few decades, tremendous progress has been achieved in the early detection and treatment of breast cancer. However, the prognosis remains unsatisfactory, and the underlying processes of carcinogenesis are still unclear. The purpose of this research was to find out the relationship between MIAT, FOXO3a, and miRNA29a-3p and evaluated the expression levels of them in breast cancer tissue compared to whole blood and their potential as a noninvasive biomarker in whole blood in breast cancer. Whole blood and breast cancer tissue are taken from patients before radiotherapy and chemotherapy. Total RNA was extracted from breast cancer tissue and whole blood to synthesize complementary DNA (cDNA). The expression of MIAT, FOXO3a and miRNA29a-3p was analyzed by the RT-qPCR method and the sensitivity and specificity of them were determined by the receiver operating characteristic (ROC) curve. Bioinformatics analysis was used to understand the connections between MIAT, FOXO3a, and miRNA29a-3p in human breast cancer in order to develop a ceRNA (competitive endogenous RNA) network. We identified that in ductal carcinoma breast cancer tissue and whole blood, MIAT and FOXO3a were more highly expressed, while miRNA29a-3p was lower compared with those in non-tumor samples. There was a positive correlation between the expression levels of MIAT, FOXO3a, and miRNA29a-3p in breast cancer tissues and whole blood. Our results also proposed miRNA29a-3p as a common target between MIAT and FOXO3a, and we showed them as a ceRNA network. This is the first study that indicates MIAT, FOXO3a, and miRNA29a-3p as a ceRNA network, and their expression was analyzed in both breast cancer tissue and whole blood. As a preliminary assessment, our findings indicate that combined levels of MIAT, FOXO3a, and miR29a-3p may be considered as potential diagnostic biomarkers for breast cancer.